N997B: Phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM): Updated results and correlative laboratory analysis.

被引：0

作者：

Galanis, E

Buckner, JC

Maurer, MJ

Hidalgo, M

Kreisberg, JI

Peralba, J

Jenkins, RB

Walsh, DJ

机构：

[1] Mayo Clin, Coll Med, Rochester, MN USA

[2] Johns Hopkins Univ, Baltimore, MD USA

[3] UTHSCSA, San Antonio, TX USA

[4] N Cent Canc Treatment Grp, Rochester, MN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：115S / 115S

页数：1

共 12 条

[1] NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM).
Galanis, E
Buckner, JC
Maurer, M
Ballman, K
Hidalgo, M
Kreisberg, JI
Boni, J
James, CDD
Jenkins, RB
Walsh, DJ
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 107S - 107S
[2] Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Chang, SM
Wen, P
Cloughesy, T
Greenberg, H
Schiff, D
Conrad, C
Fink, K
Robins, HI
De Angelis, L
Raizer, J
Hess, K
Aldape, K
Lamborn, KR
Kuhn, J
Dancey, J
Prados, MD
INVESTIGATIONAL NEW DRUGS, 2005, 23 (04) : 357 - 361
[3] Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Susan M. Chang
Patrick Wen
Timothy Cloughesy
Harry Greenberg
David Schiff
Charles Conrad
Karen Fink
H. Ian Robins
Lisa De Angelis
Jeffrey Raizer
Kenneth Hess
Ken Aldape
Kathleen R. Lamborn
John Kuhn
Janet Dancey
Michael D. Prados
Investigational New Drugs, 2005, 23 : 357 - 361
[4] Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study
Galanis, E
Buckner, JC
Maurer, MJ
Kreisberg, JL
Ballman, K
Boni, J
Peralba, JM
Jenkins, RB
Dakhil, SR
Morton, RF
Jaeckle, KA
Scheithauer, BW
Dancey, J
Hidalgo, M
Walsh, DJ
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5294 - 5304
[5] NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients
Sarkaria, J. N.
Galanis, E.
Wu, W.
Giannini, C.
Jaeckle, K. A.
Doyle, L.
Uhm, J.
Brown, P.
Dietz, A. B.
Buckner, J.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[6] Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks
Sarkaria, Jann N.
Galanis, Eva
Wu, Wenting
Dietz, Allan B.
Kaufmann, Timothy J.
Gustafson, Michael P.
Brown, Paul D.
Uhm, Joon H.
Rao, Ravi D.
Doyle, Laurence
Giannini, Caterina
Jaeckle, Kurt A.
Buckner, Jan C.
CLINICAL CANCER RESEARCH, 2010, 16 (22) : 5573 - 5580
[7] N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM)
Galanis, E.
Jaeckle, K. A.
Maurer, M. J.
Reid, J. M.
Ames, M. M.
Giannini, C.
Hardwick, J. S.
Moore, D. F., Jr.
Zwiebel, J. A.
Buckner, J. C.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[8] FEASIBILITY/TOLERABILITY RESULTS FROM A PHASE I/II STUDY OF TEMSIROLIMUS (CCI-779) AND SORAFENIB IN RECURRENT GLIOBLASTOMA: NORTH CENTRAL CANCER TREATMENT GROUP (NCCTG) N0572
Schiff, David
Sarkaria, Jann
Decker, Paul
Buckner, Jan
Galanis, Evanthia
Dancey, Janet
Giannini, Caterina
Brown, Paul
Wiesenfeld, Martin
Jaeckle, Kurt
NEURO-ONCOLOGY, 2009, 11 (02) : 232 - 232
[9] Effect of combined therapy with temsirolimus (CCI-779), temozolomide (TMZ), and radiation (RT) in newly diagnosed glioblastoma multiforme (GBM) patients on immune suppression: Results from NCCTG N027D
Sarkaria, J. N.
Galanis, E.
Gustafson, M. P.
Dietz, A. B.
Wu, W.
Brown, P. D.
Uhm, J. H.
Giannini, C.
Jaeckle, K. A.
Buckner, J. C.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[10] Correlative tumor molecular profiling and plasma biomarker analysis in a phase II study of XL184 in patients with progressive or recurrent glioblastoma multiforme (GBM)
DePrimo, S.
Wu, B.
Huang, S.
Bautista, R.
Cancilla, B.
Vysotskaia, V.
De Groot, J.
Prados, M.
Buller, R.
Wen, P.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

← 1 2 →